


CLAIMS

[Claim 1]

A compound of the following formula:

[Formula 1]




or a pharmaceutically acceptable salt thereof.

[Claim 2]

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of the following formula


[Formula 2]



[Claim 3]

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of the following formula

[Formula 3]



[Claim 4]

A composition comprising the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[Claim 5]

A composition for use in inhibiting HDAC activity, comprising the compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[Claim 6]

Use of the composition of claim 4 in the manufacture of a medicament for the treatment of conditions selected from neurological disorders, memory or cognitive impairment or dysfunction, learning extinction disorders, fungal diseases or infections, inflammatory diseases, blood diseases, mental disorders, and neoplastic diseases.

[Claim 7]

The use of claim 6, wherein the condition is:

- a. Alzheimer's disease, Huntington's disease, amnesia due to seizures, schizophrenia, Rubinstein-Taybi syndrome, Rett syndrome, depression, fragile X syndrome, Lewy body dementia, vascular dementia, frontotemporal lobar degeneration (frontotemporal dementia, FTD), FTD-GRN, ADHD, dyslexia, bipolar disorder and autism, traumatic head injury, attention deficit disorder, anxiety disorder, conditional fear response, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), phobia disorder, social anxiety disorder, recovery from substance dependence, age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), ataxia, Parkinson's disease, or dysfunction or cognitive dysfunction associated with a social disorder, cognitive disorder, or learning disorder associated with Parkinson's disease dementia;
- b. a blood disorder selected from acute myelogenous leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, and sickle cell anemia;

- c. a neoplastic disease; or
- d. a learning extinction disorder selected from fear extinction and post-traumatic stress disorder.

[Claim 8]

The use of claim 7, wherein the condition is Alzheimer's disease, Huntington's disease, frontotemporal dementia, Friedreich's ataxia, post-traumatic stress disorder (PTSD), Parkinson's disease, or recovery from material dependence.